menu

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.

    Released July 25, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.

    Released July 25, 2017

Facebook Comments

Programs 9/28/21